
India Regulates Stem Cell Therapies Under Drug Laws
The story in brief
India's new drug rules bring stem cell products, gene therapies, and xenografts under the same regulatory framework as recombinant DNA-derived drugs. The changes aim to improve clarity and ease of doing business while ensuring affordability. Manufacturers cannot exploit procedural relaxations to raise prices, and companies launching similar drugs within 12 months will only need to notify the NPPA via Form IA.